Journal Mobile Options
Table of Contents
Vol. 212, No. 4, 2006
Issue release date: May 2006
Dermatology 2006;212:327–337

Epidemiology of Psoriasis

Review and the German Perspective

Schäfer T.
Institute of Social Medicine, University Clinics of Schleswig-Holstein, Lübeck, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


According to population-based European studies, 2–3% of the population are affected by psoriasis. However, commonly accepted and validated diagnostic criteria are lacking. Psoriasis patients, compared to those with other dermatological disorders, are among those who suffer the highest impact on their quality of life, and this affection is comparable to other common diseases. Several lifestyle factors including alcohol and smoking have been associated with psoriasis. There is also evidence for associations with other diseases including cancer. Treatment of psoriasis engenders considerable costs, which should always be taken into account together with the relevant clinical outcome parameters. Prevention of psoriasis is crucial, as in the case of other common chronic diseases where causative treatments are lacking, but has barely been studied.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Naldi L: Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:121–128.
  2. Christophers E: Psoriasis – Epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314–320.
  3. Plunkett A, Marks R: A review of the epidemiology of psoriasis vulgaris in the community. Australas J Dermatol 1998;59:225–232.

    External Resources

  4. Langley R, Krueger G, Griffiths C: Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64(suppl 2):ii18–ii23.
  5. EMEA, European Medicines Agency: Committee for medicinal products for human use: guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. 2004,
  6. Naldi L, Tognoni G, Cainelli T: Analytic epidemiology in psoriasis. J Invest Dermatol 1994;102:19S–23S.

    External Resources

  7. Bell L, Sedlack R, Beard C, Perry H, Michet C, Kurland L: Incidence of psoriasis in Rochester, Minn, 1980–1983. Arch Dermatol 1991;8:1184–1187.
  8. Krueger G, Duvic M: Epidemiology of psoriasis: clinical issues. J Invest Dermatol 1994;102:14S–18S.

    External Resources

  9. Stern R: Epidemiology of psoriasis. Dermatol Clin 1995;13:717–722.
  10. Rzany B, Naldi L, Schäfer T, Stern R, Williams H: The diagnosis of psoriasis: diagnostic criteria (letter). Br J Dermatol 1998;138:917.
  11. Rzany B, Philipp A, Schäfer T: Validierung und Reproduzierbarkeit von Kriterien zu Diagnose und Schweregrad der Psoriasis. Allergo J 1997;7:367–368.
  12. Schäfer T, Kipferler P, Drzimalla K, Simon D, Borelli S, Ring J: Evaluation der ISAAC-Fragen zum atopischen Ekzem: Vergleich mit einer Kontrollgruppe von Psoriasis-Patienten. Allergo J 1999;8:297–300.
  13. Lindegard B: Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986;172:298–304.
  14. Gaston L, Lassonde M, Bernier-Buzzanga J, Hodgins S, Crombez J: Psoriasis and stress: a prospective study. J Am Acad Dermatol 1987;17:82–86.
  15. Stern R, Lange R: Cardiovascular disease, cancer and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol 1988;3:197–201.

    External Resources

  16. Lomholt G: Psoriasis: Prevalence, Spontaneous Course and Genetics – A Census Study on the Prevalence of Skin Disease on the Faröer Islands. Copenhagen, GEC, GAD, 1963.
  17. Hellgren L: Psoriasis. Stockholm, Almqvist & Wiksell, 1967.
  18. Larsson P, Liden S: Prevalence of skin diseases among adolescents 12–16 years of age. Acta Derm Venereol (Stockh) 1980;60:415–423.
  19. Barisic-Drusko V, Paljan D, Kansky A, Vujasinovic S: Prevalence of psoriasis in Croatia. Acta Derm Venereol Suppl (Stockh) 1989;146:178–179.
  20. Rea J, Newhouse M, Halil T: Skin disease in Lambeth: a community study of prevalence and use of medical care. Br J Prev Soc Med 1976;30:107–114.
  21. Brandrup F, Green A: The prevalence of psoriasis in Denmark. Acta Derm Venereol 1981;61:344–346.
  22. Kavli G, Forde O, Arnesen E, Stenvold S: Psoriasis: familial predisposition and environmental factors. Br Med J 1985;291:999–1000.
  23. Naldi L, Colombo P, Benedetti Placchesi E, Piccitto R, Chatenoud L, La Vecchia C, Centers PS: Study design and preliminary results from the pilot phase of the Praktis study: self-reported diagnoses of selected skin diseases in a representative sample of the Italian population. Dermatology 2004;208:38–42.
  24. Schäfer T, Nienhaus A, Haupt G, Vieluf D, Nagel S, Berger J, Ring J: Befunde der Hautuntersuchung und allergologischen Diagnostik; in Behörde für Arbeit GuSBdFuHH (ed): Epidemiologisches Untersuchungsprogramm Bille-Siedlung. Frankfurt am Main, Lang, 1997, pp 158–194.
  25. Schäfer T, Merkl J, Klemm E, Wichmann H, Ring J, Group KS: Does my partner cause my allergy? Allergy 2004;59:781–785.
  26. Schmitt J, Wozel G: The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005;210:194–199.
  27. Sampogna F, Sera F, Mazzotti E, Pasquini P, Picardi A, Abeni D, Group IS: Performance of the self-administered Psoriasis Area and Severity Index in evaluating clinical and sociodemographic subgroups of patients with psoriasis. Arch Dermatol 2003;139:353–358.
  28. Sampogna F, Gisondi P, Melchi C, Amerio P, Girolomondi G, Abeni D, IDI Multipurpose Psoriasis Research on Vital Experiences Investigators: Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004;151:594–599.
  29. Nevitt G, Hutchinson P: Psoriasis in the community: prevalence, severity and patients’ beliefs and attitudes towards the disease. Br J Dermatol 1996;135:533–537.
  30. Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Moerk C, Sigurgeirsson B: Epidemiology and health services research: quality of life in 6,497 Nordic patients with psoriasis. Br J Dermatol 2002;146:1006–1016.
  31. Choi J, Koo J: Quality of life issues in psoriasis. J Am Acad Dermatol 2003;49:57–61.

    External Resources

  32. Weiss S, Kimball A, Liewehr D, Blauvelt A, Turner M, Emanuel E: Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002;47:512–518.
  33. Rapp S, Feldman S, Exum M, Fleischer A, Reboussin D: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401–407.
  34. Gupta M, Schork N, Gupta A, Kirkby S, Ellis C: Suicidal ideation in psoriasis. Int J Dermatol 1993;32:188–190.
  35. Lewis V, Finlay A: Two decades experience of the Psoriasis Disability Index. Dermatology 2005;210:261–268.
  36. Sampogna F, Sera F, Abeni D, IDI Multipurpose Research on Vital Experiences Investigators: Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004;122:602–607.
  37. Finlay A, Khan G, Luscombe D, Salek M: Validation of sickness impact profile and Psoriasis Disability Index in psoriasis. Br J Dermatol 1990;123:751–756.
  38. Koo J: Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485–496.
  39. Schäfer T, Staudt A, Ring J: Entwicklung des Deutschen Instruments zur Erfassung der Lebensqualität bei Hauterkrankungen (DIELH). Hautarzt 2001;52:492–498.
  40. Schäfer T, Staudt A, Ring J: Deutsches Instrument zur Erfassung der Lebensqualität bei Hauterkrankungen (DIELH): Interne Konsistenz, Reliabilität, konvergente und diskriminante Validität und Veränderungssensitivität. Hautarzt 2001;52:624–628.
  41. Farber E, Nall M: The natural history of psoriasis in 5,600 patients. Dermatologica 1974;148:1–18.
  42. Henseler T, Christophers E: Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985;13:450–456.
  43. Elder J, Nair R, Guo S, Henseler T, Christophers E, Voorhees J: The genetics of psoriasis. Arch Dermatol 1994;130:216–224.
  44. Rahman P, Elder J: Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005;64(suppl 2):ii37–ii39.
  45. Capon F, Trembath R, Barker J: An update on the genetics of psoriasis. Dermatol Clin 2004;22:339–347.
  46. Naldi L, Parazzini F, Peli L, Chatenoud L, Cainelli T: Dietary factors and the risk of psoriasis: results of an Italian case-control study. Br J Dermatol 1996;134:101–106.
  47. Naldi L, Chatenoud L, Linder D, et al: Cigarette smoking, Body Mass Index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61–67.
  48. Abel E, DiCicco L, Orenberg E, Fraki J, Farber E: Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986;15:1007–1022.
  49. Cohen A, Kagen M, Friger M, Halevy S: Calcium channel blockers intake and psoriasis: a case-control study. Acta Derm Venereol 2001;81:347–349.
  50. Naldi L, Peli L, Parazzini F, Carrel C, Dermatology PSGotIGfERi: Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. J Am Acad Dermatol 2001;44:433–438.
  51. Coopman S, Johnson R, Platt R, Stern R: Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993;328:1670–1674.
  52. Naldi L, Parazzini F, Brevi A, et al: Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol 1992;3:212–217.

    External Resources

  53. Seville R: Stress and psoriasis: the importance of insight and empathy in prognosis. J Am Acad Dermatol 1989;20:97–100.
  54. Fortune D, Richards H, Kirby B, et al: Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol 2003;139:752–756.
  55. Henseler T, Christophers E: Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982–986.
  56. Obasi O: Psoriasis vulgaris in the Guinea Savannah region of Nigeria. Int J Dermatol 1986;25:181–183.
  57. Shbeeb M, Uramoto K, Gibson L, O’Fallon W, Gabriel S: The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol 2000;27:1247–1250.
  58. Thumboo J, Uramoto K, Shbeeb M, et al: Risk factors for the development of psoriatic arthritis: a population based nested case control study. J Rheumatol 2002;29:757–762.
  59. Yates V, Watkinson G, Kelman A: Further evidence for an association between psoriasis, Crohn’s disease and ulcerative colitis. Br J Dermatol 1982;106:323–330.
  60. Hannuksela-Svahn A, Pukkala E, Laara E, Poikolainen K, Karvonen J: Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000;114:587–590.
  61. Boffetta P, Gridley G, Lindelöf B: Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001;117:1531–1537.
  62. Javitz H, Ward M, Farber E, Nail L, Vallow S: The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002;46:850–860.
  63. Jenner N, Campbell J, Plunkett A, Marks R: Cost of psoriasis: a study on the morbidity and financial effects of having psoriasis in Australia. Australas J Dermatol 2002;43:255–261.
  64. Traupe H, Robra B: Schuppenflechte: Gesundheitsberichterstattung des Bundes/Robert Koch Institut. Statistisches Bundesamt 2002;11:1–14.
  65. Braathen L, Botten G, Bjerkedal T: Prevalence of psoriasis in Norway. Acta Derm Venereol Suppl (Stockh) 1989;142:5–8.
  66. Ashcroft D, Wan Po A, Williams H, Griffiths C: Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999;141:185–191.
  67. Baughman R, Sobel R: Psoriasis: a measure of severity. Arch Dermatol 1970;101:390–395.
  68. Feldman S, Fleischer AJ, Reboussin D, Rapp S, Exum M, Clark A, Nurre L: The self-administered Psoriasis Area and Severity Index is valid and reliable. J Invest Dermatol 1996;106:183–186.
  69. Gottlieb A, Chaudhari U, Baker D, Perate M, Dooley L: The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area and Severity Index (PASI) and Physician’s Global Assessment (PGA): a comparison. J Drugs Dermatol 2003;2:260–266.

    External Resources

  70. Langley R, Ellis C: Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol 2004;51:563–569.
  71. Finlay A, Kelly S: Psoriasis – An index of disability. Clin Exp Dermatol 1987;12:8–11.
  72. Gupta M, Gupta A: The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol 1995;75:240–243.
  73. Schmid-Ott G, Malewski P, Kunsebeck H, Ott R, Lamprecht F, Jager B: Illness-related stress in psoriasis vulgaris: validation of the Psoriasis Daily Stress Inventory. Hautarzt 2000;51:496–501.
  74. McKenna S, Cook S, Whalley D, Doward L, Richards H, Griffiths C, Van Assche D: Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol 2003;149:323–331.
  75. Kirby B, Fortune D, Bhushan M, Chalmers R, Griffiths C: The Salford Psoriasis Index: a holistic measure of psoriasis severity. Br J Dermatol 2000;142:728–732.
  76. O’Doherty C, MacIntyre C: Palmoplantar pustulosis and smoking. Br Med J 1985:861–864.

    External Resources

  77. Chaput J, Poynard T, Naveau S, Penso D, Durrmeyer O, Suplisson D: Psoriasis, alcohol and liver disease. Br Med J (Clin Res Ed) 1985;291:25.
  78. Poikolainen K, Reunala T, Karvonen J, Lauharanta J, Karkkainen P: Alcohol intake: a risk factor for psoriasis in young and middle-aged men? BMJ 1990;300:780–783.
  79. Mills C, Srivastava E, Harvey I, Swift G, Newcombe R, Holt P, Rhodes J: Smoking habits in psoriasis: a case control study. Br J Dermatol 1992;127:18–21.
  80. Duffy D, Spelman L, Martin N: Psoriasis in Australian twins. J Am Acad Dermatol 1993;29:428–434.
  81. Poikolainen K, Reunala T, Karvonen J: Smoking, alcohol and life events related to psoriasis among women. Br J Dermatol 1994;130:473–477.
  82. Naldi L, Peli L, Parazzini F: Association of early-stage psoriasis with smoking and male alcohol consumption: evidence from an Italian case-control study. Arch Dermatol 1999;135:1479–1484.
  83. McDonald C, Calabresi P: Psoriasis and occlusive vascular disease. Br J Dermatol 1978;99:469–475.
  84. Olsen J, Moller H, Frentz G: Malignant tumors in patients with psoriasis. J Am Acad Dermatol 1992;27:716–722.
  85. Lindelof B, Eklund G, Liden S, Stern R: The prevalence of malignant tumors in patients with psoriasis. J Am Acad Dermatol 1990;22:1056–1060.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50